ArticleBone marrow transplantation2014
Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT.
Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 52 citations in OpenAlex.
- Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study.Bone marrow transplantation · 2017Trial
- Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation.Journal of immunology research · 2017Trial
- Real-world clinical experience with NGS-based chimerism analyses in haematopoietic stem cell transplant patients.British journal of haematology · 2025Article
- Digital polymerase chain reaction quantification of hematopoietic chimerism by insertion/deletion: A personalized selection for different chimerism status.Journal of the Chinese Medical Association : JCMA · 2025Article
- Human amniotic epithelial stem cell is a cell therapy candidate for preventing acute graft-versus-host disease.Acta pharmacologica Sinica · 2024Article
- Prospects and Potential for Chimerism Analysis after Allogeneic Hematopoietic Stem Cell Transplantation.Cells · 2024Review
- Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation.Blood advances · 2023Article
- Validation of next-generation sequencing-based chimerism testing for accurate detection and monitoring of engraftment in hematopoietic stem cell transplantation.Frontiers in genetics · 2023Article
- Donor NKG2C homozygosity contributes to CMV clearance after haploidentical transplantation.JCI insight · 2022Article
- Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML.Frontiers in oncology · 2022Review
- The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2022Article
- Living Donor Liver Transplantation for Hepatic Venoocclusive Disease/Sinusoidal Obstruction Syndrome Originating from Hematopoietic Stem Cell Transplantation.Case reports in transplantation · 2022Article
- Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children.Bone marrow transplantation · 2021Article
- A practical guide to chimerism analysis: Review of the literature and testing practices worldwide.Human immunology · 2021Review
- Quantitative PCR-based chimerism in bone marrow or peripheral blood to predict acute myeloid leukemia relapse in high-risk patients: results from the KIM-PB prospective study.Haematologica · 2020Article
- Article
- Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.Blood advances · 2019Article
- Impact of early chimerism status on clinical outcome in children with acute lymphoblastic leukaemia after haematopoietic stem cell transplantation.BMC cancer · 2019Article
- Current Trends in Applications of Circulatory Microchimerism Detection in Transplantation.International journal of molecular sciences · 2019Review
- Systematic comparison of donor chimerism in peripheral blood and bone marrow after hematopoietic stem cell transplantation.Blood cancer journal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluates the prognostic significance of quantitative chimerism to monitor minimal residual disease and predict relapse in acute leukemia (AL) patients following allogeneic hematopoietic SCT (HSCT). The quantitative chimerism levels of 129 AL patients were measured using RQ-PCR based on 29 sequence polymorphisms. Receiver-operating characteristic curve indicated that the optimal cutoff point to predict an inevitable relapse was 1.0%, which results in 100.0% sensitivity and 79.6% specificity.The relapse rate of patients with chimerism >1.0% at 2 years was 55.0%, whereas that for patients with chimerism <1.0% was 0%(P=0.000). Quantitative chimerism >1.00% indicated a higher probability of relapse. Cox multivariate analysis indicated that quantitative chimerism >1.00% was associated with lower disease-free survival (hazard ratio (HR)=10.825; 95% confidence interval (CI) =4.704-24.912, P=0.000) and lower OS (HR=8.681; 95% CI=3.728-20.212, P=0.000). Patients (24/47 with quantitative chimerism >1.00%) who received preemptive modified DLI immunotherapy had significantly lower relapse rate (37.5%) than those (n=9) who did not (100%; P=0.001). Thus, quantitative chimerism is an independent prognostic factor that predicts clinical outcomes after HSCT and provides a guide for suitable interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.